BRPI0921758A2 - bifidobacterium longum - Google Patents

bifidobacterium longum

Info

Publication number
BRPI0921758A2
BRPI0921758A2 BRPI0921758A BRPI0921758A BRPI0921758A2 BR PI0921758 A2 BRPI0921758 A2 BR PI0921758A2 BR PI0921758 A BRPI0921758 A BR PI0921758A BR PI0921758 A BRPI0921758 A BR PI0921758A BR PI0921758 A2 BRPI0921758 A2 BR PI0921758A2
Authority
BR
Brazil
Prior art keywords
bifidobacterium longum
bifidobacterium
genome
longum
probiotic
Prior art date
Application number
BRPI0921758A
Other languages
English (en)
Inventor
Bascom Charles
Van Sinderen Douwe
Larry Charbonneau Duane
Xu Jun
O'mahony Liam
a grant Raymond
Steven Zhao Wenzhu
Song Yuli
Original Assignee
Alimentary Health Ltd
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd, Procter & Gamble filed Critical Alimentary Health Ltd
Publication of BRPI0921758A2 publication Critical patent/BRPI0921758A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/061—Addition of, or treatment with, microorganisms
    • A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A23L2/382—Other non-alcoholic beverages fermented
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Abstract

bifidobacterium longum a presente invenção refere-se às múltiplas modalidades aqui descritas compreendendo o genoma de uma cepa de bifidobactéria de bifidobacterium longum probiótica, e genes codificados pelo genoma. são descritas várias bifidobacterium longum novas.
BRPI0921758A 2008-11-11 2009-11-11 bifidobacterium longum BRPI0921758A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11351308P 2008-11-11 2008-11-11
US14998009P 2009-02-04 2009-02-04
PCT/IE2009/000079 WO2010055499A2 (en) 2008-11-11 2009-11-11 Bifidobacterium longum

Publications (1)

Publication Number Publication Date
BRPI0921758A2 true BRPI0921758A2 (pt) 2019-07-30

Family

ID=41572466

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921758A BRPI0921758A2 (pt) 2008-11-11 2009-11-11 bifidobacterium longum

Country Status (11)

Country Link
US (3) US9771624B2 (pt)
EP (1) EP2352389B1 (pt)
CN (1) CN102984955B (pt)
AU (1) AU2009315298A1 (pt)
BR (1) BRPI0921758A2 (pt)
CA (3) CA2741942C (pt)
ES (1) ES2566496T3 (pt)
MX (4) MX339907B (pt)
PL (1) PL2352389T3 (pt)
RU (1) RU2570557C2 (pt)
WO (1) WO2010055499A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010418A (es) * 2007-03-28 2010-02-18 Alimentary Health Ltd Cepas de bacterias bifidas probioticas.
MX339907B (es) 2008-11-11 2016-06-14 Alimentary Health Ltd Bifidobacterium longum.
EP2283810A1 (en) 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
EP2498790A1 (en) * 2009-11-11 2012-09-19 Alimentary Health Limited A bifidobacterium strain
BR112012011315B1 (pt) * 2009-11-11 2022-03-22 Precisionbiotics Group Limited Formulação que compreende cepa de bifidobactéria probiótica
US9259019B2 (en) 2010-11-11 2016-02-16 Mars, Incorporated Bifidobacteriumstrain
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
JP6980380B2 (ja) 2013-03-15 2021-12-15 ザ ジェネラル ホスピタル コーポレイション 短縮ガイドＲＮＡ（ｔｒｕ−ｇＲＮＡ）を用いたＲＮＡ誘導型ゲノム編集の特異性の増大
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
EP3066201B1 (en) 2013-11-07 2018-03-07 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
WO2015074054A1 (en) * 2013-11-18 2015-05-21 The Trustees Of Columbia University In The City Of New York Improving microbial fitness in the mammalian gut
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
CN114376234A (zh) * 2014-10-24 2022-04-22 进化生物系统股份有限公司 活化的双歧杆菌及其应用方法
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US9913800B2 (en) 2015-04-28 2018-03-13 The Procter & Gamble Company Compositions and methods for improving skin health
CN104894005B (zh) * 2015-04-30 2018-05-22 江苏紫石微康生物科技有限公司 一种高产胞外多糖的乳酸菌bl21及制备方法和应用
RU2614116C2 (ru) * 2015-07-21 2017-03-22 Головин Михаил Анатольевич Способ получения пробиотической композиции
RU2018105356A (ru) * 2015-08-27 2019-09-30 Дзе Проктер Энд Гэмбл Компани Бифидобактерия bifidobacterium longum
WO2017032897A1 (en) * 2015-08-27 2017-03-02 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US10973862B2 (en) 2015-12-11 2021-04-13 Precisionbiotics Group Limited Bifidobacterium longum for treating obesity and associated metabolic disorders
CN105907682A (zh) * 2016-05-31 2016-08-31 深圳先进技术研究院 一种产高粘性多糖的细菌的筛选方法
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3745871A1 (en) * 2018-01-29 2020-12-09 PrecisionBiotics Group Limited Bifidobacterium longum ncimb 41676
WO2019145573A1 (en) 2018-01-29 2019-08-01 Alimentary Health Limited Bifidobacterium longum ncimb 41676
EP4147704A1 (en) * 2018-01-29 2023-03-15 PrecisionBiotics Group Limited Bifidobacterium longum ncimb 41676
WO2019145572A1 (en) * 2018-01-29 2019-08-01 Alimentary Health Limited Bifidobacterium longum ncimb 41676
DK3745870T3 (da) 2018-01-29 2023-02-20 Prec Group Limited Et kombinationsprodukt til profylakse og behandling af irritabel tarmsyndrom
JP2022529054A (ja) 2019-04-17 2022-06-16 ニューテック・ベンチャーズ 持続性が強化された新規微生物を含む組成物、新規微生物とプレバイオティクスの相乗的組み合わせ、およびそのような微生物の分離方法
CN110205393B (zh) * 2019-07-03 2020-07-24 南京先声医学检验有限公司 用于检测营养代谢能力相关snp位点的引物组、应用、产品及方法
JP7013419B2 (ja) * 2019-08-07 2022-02-15 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
WO2021077543A1 (zh) * 2019-10-23 2021-04-29 江南大学 一种亚油酸异构酶及其在共轭亚油酸生产中的应用
CN112391484B (zh) * 2020-11-17 2022-12-27 江南大学 一种定量检测长双歧杆菌菌株的方法
WO2023137381A2 (en) * 2022-01-12 2023-07-20 Washington University Bifidobacterium infantis formulations
CN114507649B (zh) * 2022-02-16 2023-11-21 吉林大学 嗜热酶及一锅法高效合成udp-葡萄糖和udp-葡萄糖醛酸的方法
CN114774335B (zh) * 2022-06-22 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 具有靶向葡萄糖激酶显著降血糖和降血脂功效的长双歧杆菌070103及其应用
CN117568301A (zh) * 2023-11-16 2024-02-20 安徽农业大学 一种通过糖多孢红霉菌sace_1646基因提高红霉素产量的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
MY148872A (en) * 2006-02-15 2013-06-14 Nestec Sa Use of bifidobacterium longum for the prevention and treatment of inflammation
RU2333655C2 (ru) * 2006-07-26 2008-09-20 Государственное образовательное учреждение высшего профессионального образования Восточно-Сибирский государственный технологический университет Способ получения селенсодержащей биологически активной добавки
DK2318513T3 (da) * 2008-07-11 2012-10-22 Chr Hansen As Ny probiotisk bifidobacterium longum
MX339907B (es) 2008-11-11 2016-06-14 Alimentary Health Ltd Bifidobacterium longum.

Also Published As

Publication number Publication date
WO2010055499A3 (en) 2010-09-23
MX356598B (es) 2018-06-04
CN102984955A (zh) 2013-03-20
AU2009315298A1 (en) 2010-05-20
MX339907B (es) 2016-06-14
CA2852479C (en) 2017-01-24
PL2352389T3 (pl) 2016-07-29
RU2011120271A (ru) 2012-12-20
WO2010055499A2 (en) 2010-05-20
US20100183559A1 (en) 2010-07-22
CA2852479A1 (en) 2010-05-20
CA2741942A1 (en) 2010-05-20
MX349706B (es) 2017-08-09
RU2570557C2 (ru) 2015-12-10
MX2011005006A (es) 2011-05-24
US9771624B2 (en) 2017-09-26
CN102984955B (zh) 2015-01-07
US20180016647A1 (en) 2018-01-18
EP2352389A2 (en) 2011-08-10
US20200377961A1 (en) 2020-12-03
EP2352389B1 (en) 2016-01-06
CA2852487A1 (en) 2010-05-20
CA2852487C (en) 2017-01-31
CA2741942C (en) 2018-01-16
MX349705B (es) 2017-08-09
US10689719B2 (en) 2020-06-23
ES2566496T3 (es) 2016-04-13

Similar Documents

Publication Publication Date Title
BRPI0921758A2 (pt) bifidobacterium longum
TN2015000259A1 (en) Strain of bifidobacterium animalis ssp. animalis
EA201400836A1 (ru) Получение дитерпена
EA201390444A1 (ru) Производство бутанола из монооксида углерода рекомбинантным микроорганизмом
MX2010003371A (es) Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
WO2011008956A3 (en) Mammalian genes involved in infection
EA200900568A1 (ru) Модифицированные цианобактерии
WO2014096992A8 (en) Acetyl transferases and their use for producing carotenoids
BR112014018916A2 (pt) classe de genes de resistência a glifosato
JP2012034696A5 (pt)
EA201491848A1 (ru) Биозащита с использованием штаммов lactobacillus paracasei
DK2318513T3 (da) Ny probiotisk bifidobacterium longum
FR2928935B1 (fr) Souche de lactobacillus rhamnosus.
GB2483595A8 (en) Recombinant bacterium and methods of antigen and nucleic acid delivery
BR112014001834A2 (pt) biocontrole de nematoides
EA201491676A1 (ru) Партии рекомбинантного аденовируса с измененными концевыми областями
WO2010135836A8 (en) Novel beta-glucosidase enzymes
WO2011146527A3 (en) Mammalian genes involved in infection
BR112015009287A2 (pt) biocontrole de nematódeos
WO2010110914A3 (en) Mammalian genes involved in infection
BR112013001580A2 (pt) ''uma cepa bacterina geneticamente projetada wsj-ia produzindo alto conteúdo e alto rendimento de isovaleril espiramicina i''
BR112014004123A2 (pt) micro-organismos das espécies bacteroides xylanisolvens
IN2012DN01419A (pt)
WO2010057985A3 (en) Salmonella marker vaccine
WO2012045067A3 (en) Mammalian genes involved in infection

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]